Stanford University Study Confirms the Use of Human Beta Defensin-1 (hBD-1) as a Potential Adjuvant Therapy for Breast Cancer

A newly published study by Dr. Ramasamy Paulmurugan (2023) of Stanford University School of Medicine demonstrated that hBD-1 (human Beta Defensin-1 or DEFB1) activates cell death pathways that sensitize breast cancer cells to chemotherapy.  Dr. Carlton D. Donald, Founder and CEO of PHIGENIX, was the first to define the functional role of hBD-1 as a tumor suppressor in cancer. Dr. Donald commented, “This study supports Phigenix’s patented technology (US Patent #8,080,534), which utilizes hBD-1 as a therapy for breast cancer.”  Phigenix recently formed a strategic partnership to test novel compounds that increase hBD-1 expression and activity for treating breast and prostate cancer.